Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...

IXIFI is a biosimilar to Remicade (infliximab). It was approved by Health Canada in December 2021 for all eligible indications of the reference product.

plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (CD), fistulising Crohn’s disease and ulcerative colitis (UC). Remsima ® SC is a subcutaneous version of Celltrion’s ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

[1] "Chronic inflammatory diseases such as plaque psoriasis and psoriatic arthritis place significant burden on patients," said Mark G. Lebwohl*, MD, Icahn School of Medicine at Mount Sinai ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...

Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions. This drug can interact with certain vaccines and other medications, such as immunosuppressant ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...

BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial ...

The authors describe a series of 10 patients suffering from scleritis treated with the TNF inhibitor infliximab because this scleritis was refractory to standard therapy. Methods The authors reviewed ...